# EDGAR Filing Document

**Accession Number:** 0002095438
**File Stem:** 0001213900-25-109866
**Filing Date:** 2025-11
**Character Count:** 8422
**Document Hash:** d1b3dcfcde205d249aae116063f26c11
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-109866.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001213900-25-109866

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251113

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NewcelX Ltd.
- **CENTRAL INDEX KEY:** 0001783036
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92065
- **FILM NUMBER:** 251477283

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THE CIRCLE 6
- **STREET 2:** 8058
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **BUSINESS PHONE:** 41-41-618-80-00

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THE CIRCLE 6
- **STREET 2:** 8058
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NLS Pharmaceutics Ltd.
- **DATE OF NAME CHANGE:** 20190719
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Twito Ronen
- **CENTRAL INDEX KEY:** 0002095438

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** PINCHAS SAPIR 3
- **STREET 2:** WEIZMANN SCIENCE PARK
- **CITY:** NES-ZIONA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 00000

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**NewcelX Ltd.**

*(Name of Issuer)*

**Common Shares**

*(Title of Class of Securities)*

**H5835A109**

*(CUSIP Number)*

**Ronen Twito**<br>3 Pinchas Sapir St.<br>Weizmann Science Park<br>Ness-Ziona L3 7403626<br>972-73-7971600

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/30/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **H5835A109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ronen Twito** | Name of reporting person<br>**Ronen Twito** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**272399.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**272399.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**272399.00** | Aggregate amount beneficially owned by each reporting person<br>**272399.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.0%** | Percent of class represented by amount in Row (11)<br>**6.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) Consists of (i) 246,508 common shares, par value CHF 0.05 of NewcelX Ltd. (the "Common Shares"), and (ii) 25,891 Common Shares issuable upon vesting of restricted share units and exercisable within 60 days of October 30, 2025.

(2) Based on 4,558,378 Common Shares issued and outstanding as of October 31, 2025, as reported in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on October 29, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares

**(b) Name of Issuer:**
NewcelX Ltd.

**(c) Address of Issuer's Principal Executive Offices:**
The Circle 6, Zurich, V8, 8058

**Item 4. Purpose of Transaction**

The information set forth in Items 3 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Person holds all securities of the Issuer for investment purposes only. The Common Shares beneficially owned by the Reporting Persons were acquired as follows:

Merger Transaction

On November 4, 2024, NLS Pharmaceutics Ltd. ("NLS") entered into an Agreement and Plan of Merger, as subsequently amended, with Kadimastem Ltd. ("Kadimastem"). The merger (the "Merger") was completed in 2025, pursuant to which NLS Pharmaceutics (Israel) Ltd., a wholly owned subsidiary of NLS, merged with and into Kadimastem, with Kadimastem continuing as the surviving company and a wholly owned subsidiary of NLS. Following the Merger, the combined company was renamed NewcelX, Ltd. ("NewcelX" or the "Issuer"). In connection with the Merger, each outstanding ordinary share of Kadimastem was exchanged for NewcelX Common Shares in a final exchange ratio of 0.706 NLS Common Shares for each Kadimastem ordinary share.

As a result of the Merger, the Reporting Person, who served as the Executive Chairman and Chief Executive Officer of Kadimastem, became Executive Chairman and Chief Executive Officer of NewcelX. At the effective time of the Merger, the 349,331 Kadimastem ordinary shares previously beneficially owned by the Reporting Person were converted into 246,508 NewcelX Common Shares pursuant to the exchange ratio, and all 36,690 outstanding restricted stock units ("RSUs") previously granted to the Reporting Person were converted into 25,891 RSUs of NewcelX on equivalent terms.

Under his employment agreement with Kadimastem, the Reporting Person is entitled to an annual salary (according to the NIS to USD rate as of August 28, 2025) in an amount equivalent to $398,797 (including social benefits), which will increase to an amount equivalent to $445,714 upon completion by NewcelX of a capital raise exceeding $10 million following the Merger. In addition, the Reporting Person will also be entitled to receive a one-time bonus of $100,000 in connection with the closing of the Merger.

The Reporting Person serves as the Executive Chairman and Chief Executive Officer of NewcelX and, in such capacities, will be involved in reviewing transactions that may result in operational, strategic, financial or governance changes for NewcelX and may have influence over the corporate activities of NewcelX, including, without limitation, activities which may relate to any and all matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See the responses to rows 11 and 13 on the cover pages of this Schedule 13D for the Reporting Person.

**(b)**
See responses to rows 7, 8, 9 and 10 on the cover pages of this Schedule 13D for the Reporting Person.

**(c)**
Except as set forth in Item 4 of this Schedule 13D, the Reporting Person, to the best of Reporting Person's knowledge, has not engaged in any transaction with respect to the Common Shares during the sixty days prior to the date of filing this Schedule 13D.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information contained in Items 2, 3, 4 and 5 of this Schedule 13D is incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ronen Twito

**Signature:** /s/ Ronen Twito

**Name/Title:** Ronen Twito

**Date:** 11/13/2025